Rate My Professor Adrian Dunlop

Dunlop's research interests center on addiction medicine, including opioid dependence treatment, hepatitis C virus infection among people who inject drugs, methamphetamine withdrawal, cannabis use disorder, and smoking cessation in substance use populations. He has produced over 400 publications, comprising more than 187 peer-reviewed journal articles and 9 book chapters. Notable works include 'Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial' (2018, The Lancet Gastroenterology & Hepatology), 'Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial' (2014, JAMA Psychiatry), 'National guidelines for medication-assisted treatment of opioid dependence' (2014), and 'Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic' (2020, Harm Reduction Journal). He has co-authored 9 Australian guidelines on drug and alcohol treatment management, including the 'Long-acting injectable buprenorphine (LAIB) for opioid dependence treatment: Practice Guide (2nd Ed.)'. His influence extends to leadership in the NSW Drug and Alcohol Clinical Research Network and contributions to clinical trials and policy development. Awards include the Churchill Fellowship in 2005 for investigating opiate dependence treatment in pregnancy, Clinical Leader of the Year by Hunter New England Health in 2010, APSAD Award for Excellence in Science, Research and Practice in 2014, and James Rankin Orator for APSAD in 2015.